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Abstract 
Background  
The low FODMAP diet is a frequently used treatment for irritable bowel syndrome (IBS). Most 
research has focused on short-term FODMAP restriction however guidelines recommend that high 
FODMAP foods are reintroduced to individual tolerance. This study aimed to assess the long-term 
effectiveness of the low FODMAP diet following FODMAP reintroduction in IBS patients.  
Methods 
Patients with IBS were prospectively recruited to a questionnaire study following completion of 
dietitian-led low FODMAP education. At baseline and following FODMAP restriction (short-term) 
only gastrointestinal symptoms were measured as part of routine clinical care. Following FODMAP 
reintroduction, (long-term), symptoms, dietary intake, acceptability, food-related quality of life 
(QOL) and healthcare utilisation were assessed. Data were reported for patients who continued 
long-term FODMAP restriction (adapted FODMAP) and/or returned to a habitual diet (habitual). 
Key Results 
Of 103 patients, satisfactory relief of symptoms was reported in 12% at baseline, 61% at short-term 
follow-up and 57% at long-term follow-up. At long-term follow-up, 84 (82%) patients continued an 
‘adapted FODMAP’ diet (total FODMAP intake mean 20.6, SD 14.9g/d) compared with 19 (18%) of 
patients following a ‘habitual’ diet (29.4, SD 22.9g/d, p=0.039). Nutritional adequacy was not 
compromised for either group. The ‘adapted FODMAP’ group reported the diet cost significantly 
more than the ‘habitual’ group (p<0.001) and affected social eating (p<0.01) but there was no effect 
on food-related QOL. Healthcare utilisation was similar between both groups.  
Conclusion and Inferences 
Low FODMAP education is effective for long-term IBS management, enables a nutritionally adequate 
diet and is broadly acceptable to patients. 
3 
 
Key Points  
The low FODMAP diet is a successful treatment for irritable bowel syndrome (IBS). However, there 
are limited data on the long-term effects of the diet.  The current study assessed the long-term 
impact of the low FODMAP diet on clinical response, dietary intake, patient acceptability, food-
related QOL and healthcare use.  
Over half of patients report long-term symptom relief, the diet is nutritionally adequate and 
acceptable to patients.  
The findings support using the low FODMAP diet for long-term IBS management. 
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Introduction 
Irritable bowel syndrome (IBS) is the most commonly diagnosed gastrointestinal disorder(1) and is 
characterised by episodic abdominal pain and altered defecation(2). This heterogeneous disorder is a 
leading cause of morbidity among the general population and global prevalence is estimated at 11% 
with women more commonly affected than men(3). It has a significant impact on patients’ health-
related quality of life (QOL)(4, 5) and is associated with increased healthcare utilisation (6) and has 
significant economic consequences(1, 7). Over 80% of IBS patients report food-related symptoms and 
this is independently associated with reduced QOL(8).  
Dietary restriction of fermentable oligosaccharide, disaccharide, monosaccharide and polyols (low 
FODMAP diet) is an effective treatment for IBS symptoms, with 50-76% of patients demonstrating a 
clinical response(9-15). Randomized(10, 13, 16, 17) and non-randomized trials(14, 15, 18) demonstrate short-
term (up to 6 weeks) global and individual symptom improvement in IBS and have been reviewed 
elsewhere(19).   The diet involves restriction of high FODMAP foods for 4-6 weeks to achieve 
symptom improvement followed by systematic reintroduction to identify the tolerance threshold for 
individual FODMAPs, which enables long-term self-management of symptoms and increasing dietary 
variety. 
The low FODMAP diet is a complex intervention and should be implemented with counselling from a 
dietitian(20-22). To date, research has reported on clinical and nutritional outcomes following short-
term FODMAP restriction(10, 13). However, there are concerns regarding the nutritional adequacy of 
the diet and inadequate calcium intake following four weeks of FODMAP restriction(13). Furthermore, 
there are concerns regarding long-term acceptability of the diet(12, 18). Data on the long-term 
effectiveness, nutritional adequacy and acceptability of the low FODMAP diet are scarce. For 
example, studies have reported symptoms retrospectively(12, 23) or symptoms and acceptability 
prospectively(18, 24). However, there has been no evaluation of dietary intake or other aspects of the 
diet in relation to food-related QOL and effects on healthcare utilization in the long term.  
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The extensive elimination of foods and the likelihood that many patients that respond will require 
dietary modification in the long term, coupled with the increasing use of the low FODMAP diet 
warrants a comprehensive evaluation of long-term outcomes. Therefore, the aims of this study were 
to assess the long-term impact of the low FODMAP diet on clinical response, high and low FODMAP 
food frequency, nutritional adequacy, dietary acceptability, food-related QOL and healthcare 
utilization in patients with IBS. 
Materials and Methods 
Study design 
This study was a prospective long-term follow-up postal questionnaire study. Consecutive patients 
diagnosed with IBS in accordance with the National Institute of Health and Care Excellence (NICE) 
(abdominal pain/discomfort, bloating or change in bowel habit for at least 6 months in the absence 
of organic disease)(21) were recruited from both secondary care (Guy’s and St Thomas’ NHS 
Foundation Trust, London, UK) and primary care (Somerset Partnership NHS Foundation Trust, 
Somerset, UK). All eligible patients had been counselled on the low FODMAP diet by a specialist 
gastroenterology dietitian and had received two clinical appointments; the initial appointment for 
dietary education on FODMAP restriction (baseline) and the follow-up appointment at least 6 weeks 
later when they had been following the low FODMAP diet (short-term follow-up) at which point they 
were educated on FODMAP reintroduction. The prospective long-term follow-up performed as part 
of this study (long-term follow-up) occurred at least 6 months and no more than 18 months after 
short-term follow-up. Thus, data were collected from three time points, the first two of which were 
part of routine clinical care where only symptom data were collected.  
At baseline, patients had been instructed to restrict their intake of high FODMAP foods for at least 6 
weeks. Written guidance on suitable and unsuitable foods and appropriate low FODMAP food 
products for the restriction phase of the diet was provided. At short-term follow-up, counselling on 
FODMAP reintroduction was provided. Patients were instructed to undertake 3-day FODMAP food 
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challenges using increasing food portions to identify individual FODMAPs that triggered symptoms. 
This process enabled patients to reintroduce some high FODMAP foods to their tolerance threshold. 
Both appointments were conducted as per normal clinical practice as described elsewhere(14, 15).  
Patients were ineligible for the prospective long-term follow-up study if they had failed to attend the 
short-term follow-up clinical appointment; had experienced an acute gastrointestinal episode in the 
four weeks prior to long-term follow-up; had been diagnosed with a co-existing gastrointestinal 
disease (e.g. inflammatory bowel disease, coeliac disease), an eating disorder or a significant 
psychiatric disorder since baseline; or were unable to give informed consent.  
The study was carried out in accordance with the Declaration of Helsinki and was approved by the 
East of Scotland Research and Ethics Committee (REC reference: 13/ES/0158). Participation was 
voluntary and all data were confidential and were reported anonymously. All patients provided 
written informed consent at long-term follow-up.   
At the prospective long-term follow-up patients were asked to report their current weight and 
height and whether their weight had changed during FODMAP restriction. Patients were also asked 
to rate their current knowledge of the low FODMAP diet using a 5-point Likert scale (extremely poor; 
below average; average; above average; excellent). 
Gastrointestinal symptoms and stool output 
Data for symptoms and stool output were available for baseline, short-term follow-up (from clinical 
records) and long-term follow-up (from prospective survey). Data from baseline and short-term 
follow-up clinical appointments were matched to the long-term follow-up data using a unique 
anonymised identifier.  
Global symptom response used the question “Do you currently have satisfactory relief of your gut 
symptoms?”(25). The Gastrointestinal Symptom Rating Scale (GSRS) was used to assess the severity 
(absent, mild, moderate, severe) of abdominal pain, bloating, flatulence, burping, borborygmi, 
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urgency, incomplete evacuation, nausea, heartburn, acid regurgitation and lethargy(26). Data on stool 
frequency and consistency (Bristol stool form scale) were collected at all time points and based on 
an average for the last 7 days(27). IBS subtype was based on retrospective reporting of predominant 
stool consistency: those reporting Bristol Stool Form type 1 or 2 were classified as constipation-
predominant IBS (IBS-C), those reporting Bristol Stool Form type 6 or 7 were classified as diarrhoea-
predominant IBS (IBS-D), those reporting Bristol Stool Form type 1 or 2 and 6 or 7 were classified as 
mixed subtype IBS (IBS-M) and those reporting Bristol Stool Form type 3, 4 or 5 were classified as IBS 
unclassified (IBS-U). 
Dietary intake, acceptability and food-related quality of life 
Dietary intake was assessed at long-term follow-up using the Comprehensive Nutrition Assessment 
Questionnaire (CNAQ) which is a semi-quantitative food frequency questionnaire validated to assess 
FODMAP and nutrient intake(28). FODMAP intake was determined using an automated entry system 
available online (http://www.cnaq.com.au). Nutritional adequacy was assessed by comparison of 
nutrient intakes against the United Kingdom dietary reference values(29-31). Frequency data on the 
consumption of foods high and low in individual FODMAPs was assessed based on cut-offs(32). Each 
food frequency questionnaire food item was categorised as high or low FODMAP and, if high, which 
FODMAP(s) they contained. Food items were also categorised into food groups and subgroups to 
assess daily intakes. Low FODMAP speciality foods were included within their respective food group, 
e.g. low FODMAP cereals and grains included gluten-free bread, and low FODMAP milk included 
lactose-free cow’s milk. Additionally, daily intakes of onion and garlic were assessed as they 
contribute a large amount of fructans to the diet(33). 
The proportion of patients who consumed foods high in individual FODMAPs (fructans, galacto-
oligosaccharides, lactose, fructose, sorbitol and mannitol) at least once a week was assessed 
between groups.  
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Patients were asked to record their dietary adherence to long-term FODMAP restriction using a 4-
point Likert scale: ‘continued strict low FODMAP diet’, ‘reintroduced high FODMAP foods to 
tolerance’, ‘continued low FODMAP diet 50% of the time’, ‘returned to habitual diet’. The ‘adapted 
FODMAP’ group included the first three of these. 
Acceptability of dietary restriction was assessed at long-term follow-up using a 14-item 
questionnaire adapted from the nutrition-related QOL questionnaire(34). Questions considered the 
impact and challenges of diet on eating environment, travel, meal enjoyment, cost, shopping and 
cooking. Data were scored using a 5-point Likert scale (strongly agree, agree, neutral, disagree, 
strongly disagree).  
The impact of the low FODMAP diet on QOL was assessed at long-term follow-up using a 7-item 
questionnaire based on a generic validated food-related QOL tool (Satisfaction with Food-related 
Life)(35). Data were scored using a 5-point Likert scale (strongly agree, agree, neutral, disagree, 
strongly disagree).  
Healthcare utilisation and work absenteeism 
At long-term follow-up patients were asked to record how often they visited their general 
practitioner or gastroenterologist for gastrointestinal symptoms during the previous 12 months, 
what IBS medication they were currently taking, if it had changed since being advised on the low 
FODMAP diet and whether they were absent from work due to their gastrointestinal symptoms in 
the same period.  
Statistical analysis 
The primary outcome was global symptom relief at long-term follow-up compared with baseline. 
The sample size was calculated to detect a difference in the primary outcome assuming 60% of 
patients who had reported global symptom relief at short-term follow-up would continue to report it 
at long-term follow-up versus 10% of patients who had not reported global symptom relief at short-
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term follow-up would report it at long-term follow-up. A total of 80 completed questionnaires were 
required at 90% power for detecting a difference in the primary outcome at p=0.05 significance 
level. From previous experience of postal invitation to a dietary intake study, it was anticipated that 
at least 20% of subjects invited would complete and return the questionnaires(36), thus it was 
assumed that 380 patients would be invited to achieve the sample size requirement.  
Returned questionnaires were excluded from analysis if more than 10% of questions had not been 
answered. Individual symptom responses assessed by the GSRS were collapsed into a dichotomous 
response to report the presence or absence of ‘moderate or severe’ symptoms as previously 
reported(15). Stool frequency was reclassified into normal (once every 3 days to three times a day) or 
abnormal (less than once every 3 days or more than three times a day). Stool consistency was 
reclassified into normal (Bristol Stool Form types 3, 4 or 5) or abnormal (Bristol Stool Form types 1, 
2, 6 or 7) as previously reported(15). For dietary intake, dietary acceptability, food-related QOL, work 
absenteeism and healthcare utilisation comparisons, patients were collapsed into a dichotomous 
response set according to whether they returned to a habitual diet (‘habitual’) or continued to 
restrict high FODMAP foods (‘adapted FODMAP’) at long-term follow-up. Categorical data for dietary 
acceptability and food-related QOL were collapsed into three group response sets to provide 
clinically meaningful interpretation and data distribution for analysis. 
All data were analysed using SPSS, version 22 (SPSS Inc, Chicago, IL, USA). Demographic and baseline 
symptoms were analysed descriptively. Data are reported as mean ± standard deviation (SD) with 
95% confidence intervals for continuous data and n (%) for categorical data, unless otherwise 
indicated. A Bonferroni correction was applied for multiple comparisons where required. Statistical 
significance was considered where p<0.05.  
Macronutrient and micronutrient intakes were assessed for adequacy in comparison to the UK 
recommendations. Food frequency intakes from the food frequency questionnaire were converted 
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to daily intakes using previously published conversion factors(37). Daily intakes were adjusted to 
account for the total number of foods reported as consumed by each subject.  
Results 
A total of 375 (n=309 secondary care, n=66 primary care) patients were eligible and invited to 
participate in the study. Of these, 232 did not respond to the invitation to participate, thus 143 were 
consented and recruited (Figure 1). Thirty patients agreed to take part initially but did not return the 
questionnaire while seven withdrew stating lack of time or personal reasons, and three patients 
returned incomplete questionnaire and were excluded from analysis. Therefore, 103 patients were 
analysed at long-term follow-up (Table 1) with 74 from secondary care and 29 from primary care. All 
baseline demographics were similar between groups except for gender and age.  There were 
significantly fewer males from primary care (females from secondary care 50 (49%), females from 
primary care 26 (25%), males from secondary care 24 (23%), males from primary care 3 (3%); 
p=0.022) and the patients recruited from secondary care were significantly younger than the 
patients recruited from primary care (secondary care 45.3±15 years vs primary care 56.6±12 years; 
p<0.001). At baseline 20 patients had IBS-C, 39 patients had IBS-D, 21 patients had IBS-M and 23 
patients had IBS-U. 
Gastrointestinal symptoms and stool output 
At baseline, 12 (12%) patients reported satisfactory symptom relief, which increased to 63 (61%) 
patients at short-term follow-up (FODMAP restriction) and to 59 (57%) patients at long-term follow-
up (Figure 2; p=0.003). There were no significant differences for satisfactory relief between settings 
at baseline (secondary care 8 (8%) vs primary care 4 (4%); p=0.671), short-term follow-up relief 
(secondary care 42 (41) vs primary care 21 (20%); p=0.143) and long-term follow-up relief 
(secondary care 41 (40%) vs primary care 18 (18%); p=0.539). Of the 63 patients with satisfactory 
relief at short-term follow-up, 44 (70%) maintained this in the long term. The proportion of patients 
reporting presence of individual symptoms significantly decreased over time (Figure 3). Specifically, 
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abdominal pain, bloating and flatulence were reported in over 60% of patients at baseline and 
decreased by at least a third at long-term follow-up. There was a significant reduction in the 
proportion of patients reporting abnormal stool frequency (baseline 21%; short-term follow-up 7%; 
long-term follow-up 7% p<0.001) and abnormal stool consistency (baseline 65%; short-term follow-
up 43%; long-term follow-up 42% p=0.001) (Cochran test). 
Dietary intake, acceptability and food-related quality of life 
At long-term follow-up, 84 (82%) patients continued to follow an ‘adapted FODMAP’ diet while 19 
(18%) returned to a ‘habitual’ diet. There were no significant differences between groups at long-
term follow-up for energy and nutrient intakes, except for folate and vitamin A which were both 
higher in the ‘adapted FODMAP’ group compared with the ‘habitual’ group (Table 2). At least 95% of 
patients met the appropriate dietary reference value for energy and the majority of nutrients in both 
groups. Total carbohydrate and calcium intakes, which have previously been reported as lower than 
controls in short-term low FODMAP diet studies(9, 13), were not different between the ‘adapted 
FODMAP’ group compared with the ‘habitual’ group (total carbohydrate: 250±94.4g/d vs 
252±95.5g/d, p=0.925; calcium: 960±608mg/d vs 1168±695mg/d, p=0.230, respectively).  
Total FODMAP intake was significantly lower for the ‘adapted FODMAP’ group (20.6±14.9g/d) 
compared with the ‘habitual’ group (29.4±22.9g/d, p=0.039; Table 2). No significant differences were 
noted between the groups for individual FODMAP intakes although there was a trend for lower 
lactose intake in the ‘adapted FODMAP’ group compared with the ‘habitual’ group (10.4±12.7g/d vs 
16.9±19.4g/d, p=0.072).  
Patients in the ‘adapted FODMAP’ group reported a significantly lower overall intake of high 
FODMAP food groups (1195±658g/d vs 1751±1015g/d, p=0.004) and a significantly higher overall 
intake of low FODMAP food groups (2770±1236g/d vs 1857±983g/d, p=0.003) than patients in the 
‘habitual’ group (Table 3). There were similar overall intakes between groups for high and low 
FODMAP cereals and grains and the only significant findings for sub-groups of cereals and grains sub-
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group were that the ‘adapted FODMAP’ group had a higher intake of low FODMAP bread (difference 
27.04g/d, p=0.022) and a lower intake of high FODMAP pasta (difference -26.7g/d, p=0.010) 
compared with the ‘habitual’ group. The ‘adapted FODMAP’ group reported a higher intake of low 
FODMAP milk and milk products (difference 415g/d, p=0.023), specifically low FODMAP milk 
(difference 393g/d, p=0.024), and low FODMAP vegetables (difference 220g/d, p=0.020) and a lower 
intake of fats and oils (difference -11.4g/d, p=0.003) compared with the ‘habitual’ group.  
Patients in the ‘adapted FODMAP’ group consumed significantly less onion and garlic than patients 
in the ‘habitual’ group (onion: (11.4±19.1g/d vs 22.9±27.2g/d, p-0.032; garlic 0.32±0.63g/d vs 
1.25±1.83g/d, p<0.001).  
Significantly fewer patients in the ‘adapted FODMAP’ group ate high fructan foods at least once a 
week (21% vs 30% p<0.001) or foods containing high levels of free-fructose at least once a week 
(17% vs 27% p<0.001) compared with the ‘habitual’ group, and there were no differences between 
groups for foods containing high levels of lactose, galacto-oligosaccharides, sorbitol or mannitol 
(Table 4). 
There were no significant differences between groups for the majority of components of dietary 
acceptability (Table 5) except for the following. Seventy-two (86%) patients in the ‘adapted 
FODMAP’ group reported their diet was more expensive than prior to following the diet, compared 
with only 8 (42%) patients in the ‘habitual’ group (p<0.001). The ‘adapted FODMAP’ group reported 
increased difficulty eating out at restaurants compared with the ‘habitual’ group (66 (79%) vs 11 
(58%) p=0.013), eating at family and friends’ houses (61 (72%) vs 9 (48%) p=0.009) and eating when 
travelling (63 (76%) vs 9 (48%) p=0.014). However, there were no significant differences for any of 
the components of food-related QOL between groups (Table 5). 
13 
 
Healthcare utilisation and resources 
There were no significant differences for healthcare utilisation between the ‘adapted FODMAP’ and 
‘habitual’ groups for either visiting a GP (33 (39%) vs 9 (47%) p=0.431) or gastroenterologist (34 
(41%) vs 8 (42%) p=0.390). Additionally, there were no significant differences for the numbers of 
days absent from work between groups with 15 (18%) ‘adapted FODMAP’ patients vs 3 (16%) 
‘habitual’ diet patients (p=0.775) taking at least 3 days off work in the last 12 months due to 
gastrointestinal symptoms. 
Approximately half of patients reported taking no medication at long-term follow-up, 39 (46%) of 
the ‘adapted FODMAP’ vs 10 (53%) of the ‘habitual’ group (p=0.625). Since low FODMAP advice, 
significantly more patients in the ‘adapted FODMAP’ group, 22 (26%) ceased medication compared 
with only 1 (5%) patient in the ‘habitual’ group (p=0.048). For the ‘adapted FODMAP’ group, 11 
(13%) patients started new medication compared with 3 (16%) in the ‘habitual’ group (p=0.757) and 
3 (4%) of the ‘adapted FODMAP’ group reported a change in medication over the past 12 months 
compared with no patients in the ‘habitual’ group (p=0.403).  
Patients in the ‘adapted FODMAP’ group had a greater dependency on supplementary resources to 
support their diet than those in the ‘habitual’ group (p<0.001), with just under half of ‘adapted 
FODMAP’ patients (42%) using dietary information provided by the dietitian, 19% using websites 
with low FODMAP recipes and 18% using low FODMAP cookbooks.  
Discussion 
This is the first study to comprehensively report on the long-term implications of the low FODMAP 
diet in patients with IBS 6-18 months following dietitian-led education. A majority of patients (82%) 
educated on the low FODMAP diet continued with a personalised adaptation of the diet to self-
manage their symptoms in the long term and 57% of all patients who received low FODMAP 
education continued to report long-term satisfactory relief. Nutritional requirements were met by 
the majority of patients and long-term nutritional adequacy was not compromised when compared 
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with the ‘habitual’ diet group. Overall, patients found the ‘adapted FODMAP’ diet acceptable and it 
did not negatively affect their food-related QOL, healthcare utilization and work absenteeism more 
than patients who had returned to a ‘habitual’ diet.  
Our finding that dietary adherence to the low FODMAP diet is maintained in the long term and is 
associated with improved symptom response is indicative of the therapeutic value of the diet for 
long-term management.  Short-term studies have demonstrated consistent and reproducible 
findings on overall symptoms(10, 13, 14, 16, 17) and emerging, long-term data is also supportive.  After a 
median of 16 months following FODMAP education, 86% of patients with IBS and inflammatory 
bowel disease reported a partial (54%) or full (32%) symptom response to the diet(23), consistent 
with our findings.  An earlier retrospective study, which investigated adherence and clinical 
effectiveness of a partial low FODMAP diet (fructose and fructan restriction) found that at 14 
months follow-up 77% of patients were adherent to the diet with 76% reporting significant 
improvement in abdominal symptoms(12).  Prospective data on adherence are similar to our current 
study; 76% of participants were adherent to the low FODMAP diet at a mean 16 month follow-up, 
but satisfaction with symptom response was slightly greater at 72% of patients than that observed 
herein(18). In a randomised non-blinded trial which compared the low FODMAP diet with 
hypnotherapy, 82% of patients who had responded to the diet maintained satisfactory relief of 
symptoms at 6 months, equating to 58% of all patients who had received dietary advice(24). 
Cumulatively, long-term adherence to the low FODMAP diet is not only maintained in the majority of 
patients but is associated with significant improvement in symptom response.  The variation 
observed between studies may be explained, at least in part, by differences in study design such as 
the high level of response bias in retrospective studies.   
Individual symptom severity reduced at both short- and long-term follow-up. Significant reductions 
in abdominal pain, bloating, flatulence, incomplete evacuation and lethargy were reported, with 
pain, bloating and flatulence decreasing by more than one third in the long term.  These findings are 
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consistent with existing short(10, 13, 14, 16, 17) and long-term literature (18, 23, 24, 38) as well as a recent 
systemic review and meta-analysis(39). The study cohort had a low reporting of abnormal stool 
frequency at baseline which is not uncommon in IBS due to its relapsing and remitting nature. The 
enduring symptom alleviation associated with the diet is a remarkable advantage of FODMAP 
therapy particularly compared to pharmaceutical management where symptom relief is limited at 
best(40).  Dietary management of IBS is associated with increased feelings of self-control and 
empowerment(41) and may foster greater long-term self-management.  
The lack of robust long-term nutrient data and the identification of at risk nutrients in short-term 
studies(14) have raised questions regarding the nutritional adequacy, and therefore suitability, of the 
diet for long-term management.  A key finding herein is that an ‘adapted FODMAP’ diet maintained 
for 6-18 months achieved nutritional adequacy and any deficits in energy or nutrient intakes were 
similar to those expected in the background population(42).  
In short-term studies of the low FODMAP diet, total carbohydrate intakes of 200 g/d have been 
observed following FODMAP restriction(9, 13) however the current study reports a 20% higher total 
carbohydrate intake.  A gluten-free diet for management of coeliac disease is associated with a 
similar trend, that is a reduction in carbohydrate intake observed in patients new to the diet 
followed by an increase in experienced users(43, 44). There was no reduction in long-term dietary fibre 
intake. Data on dietary fibre intakes in short-term studies are inconsistent. Two studies report 
similar levels to baseline(13, 45) while another shows a significant reduction in intake following 
FODMAP restriction(9). A reduction in dietary fibre intake during FODMAP restriction is plausible 
given the stringent reduction of some staple cereals and legumes. However, in the long term we 
observed a greater proportion of patients meeting the dietary fibre nutrient requirements on an 
‘adapted FODMAP’ diet having reintroduced foods high in FODMAPs to individual tolerance than for 
those patients who had returned to a ‘habitual’ diet. This may be due to increased familiarity with 
the diet and greater understanding of low-FODMAP high-fibre food choices.  
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Previous research suggests that FODMAP restriction leads to lower calcium intakes in the short 
term(13). In the current study, mean calcium intakes were adequate and there was no difference in 
the proportion of patients that achieved their calcium requirement on an ‘adapted FODMAP’ diet 
compared with a ‘habitual’ diet. This may be due to a significant increase in lactose-free milk 
consumption (including calcium fortified plant-based milks) in the ‘‘adapted FODMAP’’ group such 
that calcium levels were maintained.  
This is the first study to evaluate the intake of foods and food groups in patients following a low 
FODMAP diet. Patients who continued to follow an ‘adapted FODMAP’ diet had a lower intake of 
garlic, onion, ready-meals, some high fructan cereal-based foods (e.g. pasta), high FODMAP sugars 
(e.g. honey) and high FODMAP miscellaneous and processed foods compared with the ‘habitual’ 
diet.  Cereal products including pasta, wheat bran and breakfast cereals have previously been 
identified as symptomatic triggers and the reduction of these is unsurprising(46). A reduced intake of 
high fat foods and miscellaneous and processed high FODMAP foods for the ‘adapted FODMAP’ 
group signifies a move towards less high-fat, energy dense food options and may, in part, explain the 
reported weight loss observed in over 40% of those on an ‘adapted FODMAP’ diet. Previously, 
patients with IBS report greater induction of symptoms with fatty foods compared to controls(47) and 
those with IBS show hypersensitivity to lipid infusions compared to healthy individuals(48).  
Interestingly,  different proportions of fat, protein and carbohydrate may aggravate IBS, particularly 
IBS-C, via hormonal mediators of gut endocrine cells which are understood to regulate 
gastrointestinal functions including visceral sensation, motility and secretion(49).  In clinical practice, 
dietary manipulation of carbohydrate or fat or an increase in protein intake are associated with 
symptom improvements in some patients(49).  
An increase of low FODMAP fruit and vegetables as seen here is equivalent to two portions of fruit 
and vegetables daily, again indicative of more healthful dietary patterns in the ‘adapted FODMAP’ 
group. Recent guidelines for IBS report that in a heterogeneous IBS population, lower intakes of fruit 
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and vegetables and higher intakes of fast foods have been reported to be involved in symptom 
generation although the evidence is insufficient to indicate that dietary habits have a role to play(22). 
Thus, if a low FODMAP diet can improve dietary habits and decrease overall intake of foods high in 
fat in the long term; it may have additional benefits to health and warrants further research.  
Further investigation to determine which individual FODMAPs and high FODMAP foods can be 
successfully reintroduced is of great interest and may help to determine whether any specific 
FODMAPs or foods are more likely to be tolerated, and which FODMAPs might be associated with 
provocation of specific symptoms.  
A reduction in body weight has been observed in individuals randomised to a low FODMAP 
compared with ‘habitual’ diet(13) and a reduction in energy intake in another study(9). Despite energy 
intake not being measured at baseline in the current study, 42% of patients reported weight 
reduction at long-term follow-up, this may be due to adopting a healthier eating pattern as 
described above. Weight and weight loss was self-reported and should be interpreted with 
caution(50). 
To the best of our knowledge, this is the first study to investigate the long-term acceptability of the 
low FODMAP diet. We report the diet causes disruption for eating out and with family/friends. 
Consistent with a recent retrospective study, the diet was associated with increased cost(23).  All of 
these issues can be addressed during dietetic consultation(14, 15). The low FODMAP diet does not 
negatively affect food-related QOL nor does it adversely affect enjoyment of meals, cooking, 
shopping and integration into current lifestyles compared with patients who consume their 
‘habitual’ diet. Given the large proportion of individuals affected by IBS and the known reduction in 
their QOL(4) alongside dissatisfaction with current treatments by at least 60% of patients(51), these 
findings are of importance. They demonstrate that the diet is not only an effective treatment but it is 
acceptable with improved QOL for this chronic disorder and patients with inflammatory bowel 
disease(17, 23, 52).   
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The economic impact of IBS is notable(1, 53, 54). Recent data suggest that IBS accounts for in excess of 
£80million in prescription costs alone and IBS patients are significant users of healthcare accounting 
for 7.5% of total outpatient visits across specialities(7). The current findings indicate that healthcare 
usage and medication use is similar among those on an ‘adapted FODMAP’ diet and a ‘habitual’ diet, 
however the expenditure appears to be slightly lower than that reported for UK patients with IBS(1). 
Further work is required to assess healthcare usage of patients who do and do not receive low 
FODMAP education.   
There are several limitations of this study. Firstly, only 27% of the original sample invited to take part 
completed the study which is lower than other similar postal questionnaire studies(18, 57).Whilst we 
acknowledge that it is possible we may have sampled a biased population of patients who had 
responded to the low FODMAP diet, global symptom data from the baseline and short-term follow-
up was similar for those who did and did not reply to the initial invite as reported previously(18).  
Over 80% of subjects were recruited from an urban setting although most did not reply or had 
moved. Half of subjects invited from a rural area were recruited to the study. The higher response 
rate among these participants may possibly reflect the less transient nature of rural communities. In 
addition, the rural population were significantly older and included a smaller proportion of males 
than the urban population perhaps due to greater work opportunities for the younger population 
and for males in the urban area compared to elsewhere as reported from national data(58). Secondly, 
the study design was a prospective questionnaire-based study that was uncontrolled and unblinded, 
thus increasing the risk of bias. Finally, given the lack of a disease activity biomarker in IBS, symptom 
evaluation was subjective and we acknowledge the limitations associated with subjective 
measures(22, 55). Dietary intake was assessed by a food frequency questionnaire which has been 
validated to assess FODMAP intake however, not in a UK population.  As with all food frequency 
questionnaires this approach can underestimate or overestimate intake of certain foods(56).  
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In summary, we report that the low FODMAP diet is an effective long-term strategy for the 
management of IBS addressing an area which has, to date, been largely unexplored(59-61).  
Conclusion 
This study prospectively evaluated the long-term impact of the low FODMAP diet on symptom 
response, dietary intake, patient acceptability and healthcare utilization in a large cohort of patients 
with IBS. Patients report that the diet is clinically effective with 57% reporting long-term satisfactory 
symptom relief. Individuals who have received comprehensive education on the low FODMAP diet 
have completed short-term FODMAP restriction followed by FODMAP reintroduction to individual 
tolerance. A low FODMAP diet can be nutritionally adequate up to 18 months after initial education 
and patients find that the diet is acceptable and does not adversely impact on food-related QOL. 
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Table 1: Demographics of irritable bowel syndrome patients at long-term follow-up 
Demographic Long-term follow-up 
(n=103) 
Secondary care 
(n=74) 
Primary care 
(n=29) 
P 
Gender      
   Female n (%) 76 (74) 50 (49) 26 (25) 0.0222 
   Male n (%) 27 (26) 24 (23) 3 (3)  
Age (years) mean ± SD 49 ± 15 45.3 ± 15 56.6 ± 12 <0.0013 
Weight (kg) mean ± SD 69.7 ± 13.7 70.5 ± 13.7 68.0 ± 13.9 0.4103 
BMI (kg/m2) mean ± SD 24.8 ± 3.9 24.5 ± 3.6 25.2 ± 4.3 0.4043 
Weight change since low FODMAP education      
   Lost weight n (%) 42 (41) 31 (30) 11 (11) 0.0642 
   Remained the same weight n (%) 48 (47) 30 (29) 18 (18)  
   Gained weight n (%) 13 (12) 13 (12) 0  
Knowledge and understanding of the low FODMAP diet n (%)1    
   Average n (%) 35 (35) 28 (27) 7 (7) 0.4652 
   Above average n (%) 55 (56) 38 (37) 17 (17)  
   Excellent n (%) 9 (9) 5 (5) 4 (4)  
1 Missing n=4 2 Chi squared between settings 3 Independent t-test between settings 
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Table 2: Intakes of energy, nutrients and FODMAPs for IBS patients at long-term follow-up  
 Intakes (mean ± SD)    Meeting requirements (DRV), n (%)  
 Habitual diet  
 
(n=19) 
Adapted  
FODMAP diet  
(n=84) 
P1 Dietary 
Reference 
Value2 
 Habitual diet 
n (%) 
Adapted  
 FODMAP diet 
n (%) 
P3 
Energy kcal/d 2219 ± 831 2147 ± 759 0.715 2605 (m)  2079 (f) 11 (58) 43 (51) 0.597 
Protein g/d 91.5 ± 38.0 99.1 ± 38.3 0.437 M 55.5 F 45 15 (79) 82 (98) 0.010 
Fat g/d 87.7 ± 45.7 70.1 ± 33.4 0.056 35% of food energy 10 (53) 26 (31) 0.073 
Carbohydrate g/d 250 ± 94.4 252 ± 95.5 0.925 50% of food energy 12 (63) 53 (63) 0.996 
    Starch g/d 122 ± 57.3 128 ± 56.9 0.696      
    Total sugars g/d4 122 ± 55.2 122 ± 62.9 0.990      
Dietary fibre g/d 24.9 ± 9.47 26.8 ± 11.5 0.500 30  14 (74) 71 (85) 0.261 
Calcium mg/d 960 ± 608 1168 ± 695 0.230 700  12 (63) 64 (76) 0.243 
Iron mg/d 12.9 ± 4.10 13.9 ± 4.70 0.411 8.7 (m) 14.8 (f) 12 (63) 57 (68) 0.694 
Zinc mg/d 12.7 ± 5.40 14.4 ± 5.35 0.231 M 9.5  F 7.0 15 (79) 79 (94) 0.058 
Magnesium mg/d 342 ± 111  385 ± 134 0.198 M 300 F 270 14 (74) 64 (76) 0.243 
Sodium g/d 2.70 ± 1.40 2.50 ± 1.40 0.849 1.6  14 (74) 60 (71) 0.843 
Potassium g/d 3.77 ± 1.20 4.30 ± 1.50 0.191 3.5  11 (58) 54 (64) 0.602 
Phosphorus mg/d 1757 ± 756 1879 ± 1340 0.704 550   19 (100) 83 (99) 0.816 
Vitamin A ug/d5 1429 ± 845 2147 ± 1482 0.045 M 700 F 600 18 (95) 77 (92) 0.652 
Thiamin mg/d 1.40 ± 0.60 1.87 ± 1.00 0.121 M 1.0 F 0.8 18 (95) 83 (99) 0.245 
Riboflavin mg/d 2.37 ± 1.10 2.97 ± 1.60 0.093 M 1.3 F 1.1 16 (84) 83 (99) 0.019 
Niacin mg/d 21.4 ± 7.00 25.37 ± 10.2 0.119 M 17 F 13 19 (100) 84 (100) 1.000 
Folate ug/d 318 ± 108 398 ± 143 0.024 200  17 (90) 83 (99) 0.087 
Vitamin C mg/d 168 ± 86.2 220 ± 143 0.129 40   19 (100) 84 (100) 1.000 
Total FODMAPS g/d 29.4 ± 22.9 20.6 ± 14.9 0.039      
   Fructo-oligosaccharides g/d 2.50 ± 1.30 2.00 ± 1.40 0.160      
   Galacto-oligosaccharides g/d 1.00 ± 0.60 1.30 ± 1.50 0.326      
   Lactose g/d 16.9 ± 19.4 10.4 ± 12.7 0.072      
   Excess fructose g/d 6.20 ± 8.10 4.70 ± 10.4 0.561      
   Sorbitol g/d 2.17 ± 1.90 1.60 ± 1.70 0.208      
   Mannitol g/d 0.60 ± 0.60 0.50 ± 0.40 0.267      
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DRV dietary reference value; 
1 Independent t-test between ‘habitual’ diet versus ‘adapted FODMAP’ diet 
2Where applicable M male 19-50 years and F female 19-50 years values are given as an example but the value may not apply if >50 years (30) 
3 Chi squared between numbers meting the requirement (DRV) for ‘habitual’ diet versus ‘adapted FODMAP’ diet 
4 included sucrose, lactose, glucose and fructose – DRV only available for free sugars so not assessed 
5Total vitamin A equivalents 
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Table 3: Dietary intake of high and low FODMAP food groups for IBS patients at long-term follow-up  
Food group 
Habitual diet 
(n=19) 
Adapted FODMAP diet 
(n=84) 
 
 
Mean ± SD (g/d) Mean ± SD (g/d) P 
Cereals and grains high FODMAP 258 ±174 194 ± 146 0.098 
Cereals and grains low FODMAP1 249 ±239 326 ± 247 0.221 
   Grain high FODMAP 21.8 ±27.1 15.79 ± 32.4 0.452 
   Grain low FODMAP 164 ±213 173 ± 177 0.859 
   Bread high FODMAP 76.6 ±75.0 61.4 ± 71.5 0.409 
   Bread low FODMAP1 1.56 ±5.31 28.6 ± 50.5 0.022 
   Breakfast cereal high FODMAP 47.4 ±46.8 43.4 ± 60.4 0.787 
   Breakfast cereal low FODMAP 23.2 ±34.8 28.6 ± 41.5 0.599 
   Pasta high FODMAP 47.5 ±55.7 20.8 ± 35.4 0.010 
   Pasta low FODMAP1 39.8 ±55.4 63.7 ± 77.3 0.204 
   Cereal products high FODMAP 29.5 ±27.4 22.7 ± 30.9 0.380 
   Cereal products low FODMAP1 20.4 ±25.7 32.5 ± 49.7 0.306 
Milk & milk products high FODMAP 688 ±820 416 ± 529 0.074 
Milk & milk products low FODMAP2 148 ±234 563 ± 777 0.023 
   Milk high FODMAP 552 ±830 295 ± 486 0.076 
   Milk low FODMAP2 82.7 ±157 476 ± 742 0.024 
   Cheese high FODMAP 7.31 ±18.3 11.8 ± 36.0 0.600 
   Cheese low FODMAP 27.5 ±38.2 29.3 ± 50.2 0.883 
   Yoghurt high FODMAP 97.5 ±141 94.5 ± 137 0.933 
   Yoghurt low FODMAP2 25.5 ±91.8 46.2 ± 103 0.422 
   Other dairy high FODMAP e.g. Ice cream 17.1 ±34.8 10.1 ± 18.2 0.211 
   Other dairy low FODMAP 7.38 ±11.6 5.91 ± 10.1 0.579 
Fruit high FODMAP 233 ±176 188 ± 226 0.412 
Fruit low FODMAP 289 ±227 460 ± 387 0.067 
Vegetables high FODMAP 196 ±122 165 ± 170 0.453 
Vegetables low FODMAP 488 ±250 708 ± 387 0.020 
Proteins 184 ±126 199 ± 111 0.601 
Fats 26.6 ±23.5 15.2 ± 12.5 0.003 
Drinks high FODMAP 219 ±472 146 ± 350 0.441 
Drinks low FODMAP 394 ±697 432 ± 536 0.791 
Sugars high FODMAP3 11.7 ±17.6 4.15 ± 6.55 0.002 
Sugars low FODMAP 15.4 ±16.8 20.5 ± 21.8 0.344 
Miscellaneous and processed high FODMAP 194 ±152 117 ± 110 0.012 
Miscellaneous and processed low FODMAP 70.2 ±104 53.8 ± 41.6 0.266 
TOTAL high FODMAP 1751 ± 1015 1195 ± 658 0.004 
TOTAL low FODMAP 1857 ± 983 2770 ± 1236 0.003 
Independent t-test 
1 Foods described as gluten-free in the food frequency questionnaire were included in this group or sub-group  
2 Foods described as lactose-free in the food frequency questionnaire were included in this group or sub-group  
3 Includes honey, sugar-free chewing gum (high in polyols)
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Table 4: The percentage of IBS patients consuming high FODMAP foods at least once a week at long-term follow-
up 
 
Consumed at least once a week (% of patients)  
 
P 
 
Habitual diet Adapted FODMAP diet 
Fructans 30.2 21.1 <0.001 
Galacto-oligosaccharides 28.8 24.5 0.11 
Lactose 22.6 19 0.183 
Free fructose 26.8 17 <0.001 
Sorbitol 30.4 27 0.201 
Mannitol 37.5 39.9 0.588 
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Table 5: Dietary acceptability and food-related quality of life of IBS patients at long-term follow-up 
  Habitual diet n (%) Adapted FODMAP diet n (%)   P 
      
 
  Agree Neutral Disagree Agree Neutral Disagree 
 
Dietary acceptability             
 
I find it easy to buy suitable foods for my current diet at my normal supermarkets or 
shops 
14 (74) 1 (5) 4 (21) 57 (68) 9 (11) 18 (21) 0.759 
I am able to buy foods suitable for my current diet at my normal supermarkets or 
shops1 
16 (85) 1 (5) 2 (10) 63 (76) 9 (11) 11 (13) 0.698 
I use high street/online speciality shops (e.g. health food shops) to buy food for my 
current diet 
7 (41) 6 (35) 4 (24) 28 (33) 14 (17) 42 (50) 0.086 
It takes extra time to shop for my current diet 8 (43) 5 (26) 6 (32) 54 (64) 11 (13) 19 (23) 0.172 
It takes extra time to cook for my current diet 8 (42) 3 (16) 8 (43) 38 (45) 11 (13) 35 (42) 0.943 
I find food labelling is adequate to allow me to confidently choose suitable foods  10 (53) 8 (42) 1 (5) 53 (63) 16 (19) 15 (17) 0.067 
The cost of my current diet is more expensive 8 (42) 9 (47) 2 (11) 72 (86) 11 (13) 1 (1) <0.001 
Does eating out at restaurants make it more difficult for you to follow your current 
diet? 
11 (58) 1 (5) 7 (37) 66 (79) 8 (10) 10 (12) 0.030 
Does eating out at friends/families make it more difficult for you to follow your current 
diet? 
9 (48) 3 (16) 7 (37) 61 (72) 15 (18) 8 (9) 0.009 
Does travel (overseas/UK) make it more difficult for you to follow your current diet? 1 9 (48) 3 (16) 7 (37) 63 (76) 11 (13) 9 (11) 0.014 
Overall, I find my current diet tasty and enjoyable 14 (74) 3 (16) 2 (10) 53 (63) 15 (18) 16 (19) 0.622 
I can incorporate my current diet easily into my life1 10 (55) 4 (22) 4 (22) 47 (56) 20 (24) 17 (20) 0.978 
My current dietary needs have created stress with my family/friends1 5 (28) 3 (17) 10 (55) 20 (24) 16 (19) 48 (57) 0.929 
Food-related quality of life             
 
Food and meals are positive elements of my life 14 (74) 3 (16) 2 (11) 57 (68) 14 (17) 13 (15) 0.842 
I am generally pleased with my food  10 (53) 7 (37) 2 (11) 47 (56) 23 (27) 14 (16) 0.643 
My life in relation to food and meals is close to my ideal1 9 (45) 5 (25) 6 (30) 25 (29) 27 (32) 32 (38) 0.329 
With regard to food, the conditions of my life are excellent 8 (42) 7 (37) 4 (21) 27 (33) 28 (34) 28 (34) 0.535 
Food and meals give me satisfaction in daily life 10 (53) 7 (37) 2 (10) 47 (56) 20 (24) 17 (20) 0.401 
I wish my meals were much more pleasant part of my life1 6 (34) 6 (33) 6 (34) 35 (42) 20 (24) 29 (35) 0.674 
When I think of my next meal, I only see problems, obstacles and disappointments1 4 (23) 5 (28) 9 (50) 15 (18) 17 (20) 52 (62) 0.189 
1 Missing n=1 
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Figure legends 
Figure 1: Study flow diagram 
Figure 2: Symptom relief for the global symptom question at each time-point 
Figure 3: Proportion of patients reporting the presence of individual gastrointestinal symptoms at 
baseline, short-term follow-up and long term follow-up (n=103) 
  Baseline  Short-term follow-up  Long-term follow-up 
 
P Significant differences between baseline and long-term follow-up 
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Figure 2 
 
 
 
Baseline Short-term follow-up Long-term follow-up
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relief of symptoms at 
long-term follow-up 
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